Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer
Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.
Category
  • Bladder Cancer
  • Genitourinary Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Management of Central Nervous System Metastases
As a result of advances in diagnosis and treatment, many patients improve with proper management and do not die of progression of these metastatic lesions. As CNS-active systemic agents are changing paradigms for the management of brain metastases, it is important to acknowledge that there is a paucity of prospective data to characterize optimal strategies regarding radiation and systemic therapy combinations or sequencing.
Category
  • Central Nervous System Cancers
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey
Clinicians need to be educated on the vast and varied impact cancer can have on individuals, the barriers to receipt of high-quality care, and the various professionals who can be part of their team to provide comprehensive care and improve patient outcomes. Information on approaches to build, maintain, and support such teams is also needed so that patients can benefit.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Team-Based Management of Immunotherapy-Related Toxicities
Education on this topic will enable clinicians to more rapidly identify when they may need to seek the expertise of disease specialists, and which specialists may be most relevant to their patients’ needs.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies
Educating clinicians about the various strategies that can be employed to improve the effective delivery of anticancer therapy will enable the incorporation of these strategies into routine clinical practice. 
Category
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia
Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of Relapsed/Refractory Multiple Myeloma
Understanding optimal sequencing for patients with relapsed/refractory multiple myeloma can be a challenge in clinical practice. A uniform treatment approach cannot be applied to all patients. Physicians and other care providers must understand the evolving therapeutic options in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Metastatic Prostate Cancer
Clinicians need to be educated on results of recent trials and on updates to the NCCN Guidelines for Prostate Cancer recommendations so that they can provide optimal disease management for patients with metastatic prostate cancer.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Updates on the Management of Immunotherapy-Related Toxicities
As the field of cancer immunotherapy continues to evolve, clinicians need to be informed about the most up-to-date strategies for managing immunotherapy-related toxicities. Providing continuing education on early recognition and effective management of immunotherapy-related toxicities is crucial to ensure optimal outcomes for an increasing number of patients treated with immunotherapy.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages